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Recent findings indicate that patients with systemic 
sclerosis have an increased risk of cardiovascular di-
sease. To determine whether patients with systemic 
sclerosis or localized scleroderma are at increased risk 
of cardiovascular disease, a cohort study of the enti-
re Danish population aged ≥ 18 and ≤ 100 years was 
conducted, followed from 1997 to 2011 by individual-
level linkage of nationwide registries. Multivariable 
adjusted Cox regression models were used to estimate 
the hazard ratios (HRs) for a composite cardiovascu-
lar disease endpoint. A total of 697 patients with lo-
calized scleroderma and 1,962 patients with systemic 
sclerosis were identified and compared with 5,428,380 
people in the reference population. In systemic sclero-
sis, the adjusted HR was 2.22 (95% confidence inter-
val 1.99–2.48). No association was seen between pa-
tients with localized scleroderma and cardiovascular 
disease. In conclusion, systemic sclerosis is a signifi-
cant cardiovascular disease risk factor, while patients 
with localized scleroderma are not at increased risk of 
cardiovascular disease. 
Key words: localized scleroderma; systemic sclerosis; cardio-
vascular risk; cardiovascular disease; inflammation; epidemio-
logy.
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Recent findings indicate that patients with systemic sclerosis (SSc) have an increased risk of cardiovas-
cular disease (CVD) (1, 2), but population-based cohort 
studies are lacking (3, 4). In addition, little is known 
about the risk of CVD in patients with localized sclero-
derma (LS).
SSc is a chronic autoimmune disease characterized by 
fibrosis of the skin and internal organs. LS, also known 
as morphea, is characterized by excessive deposition 
of collagen leading to thickening of the dermis, sub-
cutaneous tissues, or both. Depending on the subtype 
and site affected, adjacent structures, such as adipose 
tissue, muscles, joints and bones, may be involved, but 
the internal organs are not affected and no progression 
to SSc occurs (5). 
Other autoimmune diseases, such as rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE), 
are associated with increased risk of developing CVD 
(6–8). One of the reasons for this association is related 
to chronic inflammation that predisposes to atheroscle-
rosis (9–12). 
The aim of this Danish nationwide cohort study was 
to determine whether patients with LS and SSc have 
increased risk of CVD and all-cause mortality, compared 
with the general population, based on the unique Danish 
Health registers.
MATERIALS AND METHODS
Data sources and study population
The study was approved by the Danish Data Protection Agency. 
In Denmark, ethics committee approval is not required for 
register studies. The following registries were used: the Civil 
Registration System, which holds information on patient date 
of birth, sex and vital status (13); the National Patient Registry, 
which holds information on all inpatient and outpatient visits to 
Danish hospitals since 1978, with diagnoses according to the 
International Classification of Diseases (ICD) (prior to 1994, 
according to the 8th revision (ICD-8) and thereafter the 10th re-
vision (ICD-10)) (14), which was used to identify patients with 
scleroderma and to obtain information on comorbidity; and the 
Registry of Medicinal Product Statistics, which holds informa-
tion on all prescription claims since 1995 (15). All drugs are 
classified according to the Anatomical Therapeutical Chemical 
(ATC) classification. Pharmacies in Denmark are required to 
register all dispensed prescriptions.
Data on death (16), comorbidity, concomitant medication and 
socioeconomic status (17) were linked at the individual level.
The study population comprised all Danish citizens ≥ 18 and 
≤ 100 years of age from 1 January 1997 to 31 December 2011. 
All residents in Denmark have a 10-digit personal identification 
number, which is the same throughout all national registries, and 
hence register linkage is possible.
Patients with a diagnosis of LS were identified by ICD-10: 
DL940 localized scleroderma, DL940B sclerodermia circum-
scripta or DL941 scleroderma lineare, and patients with SSc by 
ICD-10: DM340 progressive systemic scleroderma, DM348 other 
forms of systemic scleroderma, DM348B systemic scleroderma 
with acrosclerosis or DM349 systemic sclerosis unspecified. It was 
decided not to include patients with DM342 systemic scleroderma 
caused by drugs or chemicals, DL903 Pasini-Pierinis atropho-
derma, and DM341 CREST syndrome because of discrepancies in 
how these codes were used. Patients with a history of CVD prior 
to the beginning of the study were excluded.
Medical treatment and co-morbidity 
The baseline (up to 6 months prior to inclusion) pharmacological 
treatment was identified by patient prescriptions (from the Danish 
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Registry of Medicinal Product Statistics) for: platelet inhibitors 
(ATC classification code: B01AC), beta-blockers (C07), renin-
angiotensin-aldosterone system inhibitors (C09), calcium anta-
gonists (C08), loop diuretics (C03C), thiazide diuretics (C03A), 
spironolactone (C03D), cholesterol-lowering drugs (C10A), 
glucose-lowering drugs (A10), non-steroidal anti-inflammatory 
drugs (NSAID) (MA01A), antidepressants (N06A), and anti-
thyroid drugs (H03B). 
Baseline comorbidity was defined by hospitalization (in the 
Danish National Patient Registry) up to 12 months prior to inclu-
sion, according to the previously validated Charlson comorbidity 
index. The comorbidity index is the established sum for the 19 
included clinical conditions, which were given weights ranging 
from 1 to 6, as follows: 1: myocardial infarct, congestive heart 
failure, peripheral vascular disease, dementia, cerebrovascular 
disease, chronic lung disease, connective tissue disease, ulcer, 
chronic liver disease, diabetes; 2: hemiplegia, moderate or se-
vere kidney disease, diabetes with end-organ damage, tumour, 
leukaemia, lymphoma; 3: moderate or severe liver disease; and 
6: malignant tumour, metastasis, or acquired immunodeficiency 
syndrome (AIDS) (18).
Outcomes
The primary endpoint of the study was a composite of cardiovas-
cular death (ICD-10 I00-I99), myocardial infarction (ICD-10 I21 
and I22) and stroke (ICD-10 I60, I61, I63 and I64). The secondary 
endpoint, all-cause mortality, was examined. Previous studies 
have demonstrated that diagnoses of acute myocardial infarction 
(AMI) and stroke in the Danish registries are accurate (19, 20).
Statistical analysis
Patients were followed from 1 January 1997 or on the subse-
quent day that the subjects reached 18 years of age, and were 
censored on 31 December 2011 or during follow-up, if an event 
or death occurred. Event rates per 1,000 person-years and 95% 
confidence intervals (95% CIs) were calculated for patients 
with LS, SSc, and for the reference population, respectively. 
Multivariable adjusted Cox regression models were used to 
estimate hazard ratios (HRs) and 95% CIs. We adjusted for a 
priori defined confounding factors, including age, calendar year, 
concomitant medication, comorbidity, socioeconomic status 
and sex. The comorbidity index score was incorporated into 
the model as a continuous variable and concomitant medication 
as a dichotomous variable. LS and SSc status at a given age 
were included as time-dependent variables, to ensure accurate 
allocation of time at risk. Comorbidity, use of medication and 
socioeconomic status were included as fixed variables obtained 
at baseline. Socioeconomic status was defined according to the 
mean yearly income in the 5 years preceding the beginning of the 
study, divided into quintiles. One-year time bands were created 
and the patient’s age was updated at each time-band. In addition, 
all analyses were repeated with inclusion of prescription drug 
use as a time-dependent variable, to ensure inclusion of conti-
nuously updated information on comorbidities in the analyses. A 
2-sided p-value < 0.05 was considered statistically significant. All 
analyses were performed with the use of SAS software (Version 
9.2, SAS Institute, Cary, NC, USA), and Stata software (Version 
11.0, StataCorp, College St., TX, USA).
RESULTS
The study comprised a total of 697 patients with LS, 
1,962 with SSc and 5,428,380 in the reference popu-
lation (Fig. 1). The incidence rate (IR) of LS was 1.1 
per 100,000 person-years and 3.1 events per 100,000 
person-years for SSc.
Fig. 1. Flowchart of the study population. AMI: acute myocardial 
infarction; CVD: cardiovascular disease.










Age, years, mean (SD) 40.2 (19.3) 38.8(17.6) 49.2 (15.7)
Female, n (%) 2,762,705 (50.9) 519 (74.5) 1,570 (80.0) < 0.00
Charlson co-morbidity scores, mean (SD) 0.02 (0.23) 0.03 (0.23) 0.14 (0.50)
Baseline medication, n (%) 
  Beta-blockers 123,641 (2.3) 22 (3.2) 63 (3.2) 0.006
  RAAS-inhibitors 104,628 (1.9) 17 (2.4) 83 (4.2) < 0.001
  Calcium antagonists 125,447 (2.3) 13 (1.9) 250 (12.7) < 0.001
  Loop diuretics 110,091 (2.0) 16 (2.3) 114 (5.8) < 0.001
  Thiazide diuretics 134,767 (2.5) 24 (3.4) 105 (5.4) < 0.001
  Spironolactone 14,293 (0.3) < 3 (NS) 11 (0.6) 0.03
  Platelet inhibitors 114,298 (2.1) 13 (1.9) 74 (3.8) < 0.001
  Cholesterol-lowering drugs 19,039 (0.4) 3 (0.4) 16 (0.8) 0.002
  Glucose-lowering drugs 69,595 (1.3) 14 (2.0) 35 (1.8) 0.03
  NSAIDs 124,741 (2.3) 18 (2.6) 78 (4.0) < 0.001
  Antidepressants 145,523 (2.7) 18 (2.6) 124 (6.3) < 0.001
  Anti-thyroid drugs 13,641 (0.3) <3 (NS) 10 (0.5) 0.06
The number of patients with localized scleroderma using spironolactone is written as <3, as it is not allowed to show numbers of cases <3, hence the percentage becomes 
”not shown”. The same rule applies to patients with localized scleroderma using anti-thyroid drugs.
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The baseline characteristics of the study population are 
shown in Table I. Follow-up time, number of events and 
incidence rates (IRs) are shown in Table II. 
Patients with SSc were associated with a significantly 
increased risk of CVD and all-cause mortality (Table 
III). In this group the adjusted HRs were 2.22 (95% CI 
1.99–2.48) and 2.66 (95% CI 2.45–2.90) for composite 
CVD and all-cause mortality, respectively. 
No association was found between patients with LS 
and CVD or all-cause mortality. In patients with LS, the 
HRs for composite CVD endpoint and all-cause mortality 
were comparable to the HRs in the reference population. 
Sensitivity analyses
The inclusion of prescription drug use as time-dependent 
information on comorbidities in the analyses did not sig-
nificantly alter the results. In the sensitivity analyses, the 
HR for the composite CVD endpoint for patients with LS 
was 0.89 (95% CI 0.67–1.18), compared with 0.96 (95% 
CI 0.72–1.27) in the main analyses; and for patients with 
SSc, the HR was 2.11 (95% CI 1.89–2.36), compared 
with 2.22 (95% CI 1.99–2.48) in the main analyses. 
Similarly, there was no difference in the results when 
stratifying the data into age categories (data not shown). 
DISCUSSION
In this Danish nationwide cohort study, SSc was a 
significant cardiovascular risk factor for the composite 
endpoint of stroke, myocardial infarction, and cardio-
vascular death, and for all-cause mortality. Patients with 
LS were not at increased risk for CVD and did not have 
increased all-cause mortality, compared with the general 
population.
The reason for the increased risk of CVD in patients 
with SSc is not clear. Atherosclerotic CVD may be due to 
the chronic inflammation (3, 9), as seen in other autoim-
mune diseases (6, 8) besides the traditional cardiovascu-
lar risk factors. Similarly, pulmonary hypertension and 
pulmonary fibrosis are probably part of the explanation 
for the increased risk of CV death in these patients. 
Chronic inflammation predisposes to atherosclerosis, 
which is the hallmark of CVD (9–12). A systematic 
review from 2011 concluded that patients with SSc had 
increased atherosclerosis compared with healthy indivi-
duals (21). Other mechanisms, by which atherosclerosis 
is believed to be promoted in connective tissue diseases is 
due to altered lipid profiles and function, autoantibodies 
and endothelial dysfunction (3, 4, 22). 
The survival of patients with scleroderma has impro-
ved over the past 30 years. Fewer scleroderma-related 
deaths are being reported, with patients living longer 
despite having the disease. Pulmonary hypertension and 
pulmonary fibrosis are the primary cause of scleroderma-
related deaths today (23).
No association was seen between CVD and patients 
with LS. In LS, the risk of having a composite CVD 
endpoint was the same as in the general population. 
This is in contrast to findings in patient with cutaneous 
lupus erythematosus without systemic involvement and 
in patients with psoriasis (8, 24). Indeed, the results in-
dicate LS as being a disease limited to the skin without 
any systemic effect.
In previous studies, SSc is mentioned as a cardiovas-
cular risk factor, and the risk of these patients having 
CVD is increased (2, 25, 26). In our study, the HR of the 
composite CVD endpoint was 2.2-fold higher for patients 
with SSc, compared with the general population in Den-
mark. A study from a UK database found an adjusted HR 
for AMI or stroke of 2.16 (95% CI 1.49–3.14) (2), a study 
from Canada showed an adjusted HR for CVD of 2.70 
(95% CI 2.07–3.51) (25) and a meta-analysis found a risk 
of ischaemic stroke with a pooled risk ratio of 1.68 (95% 
CI 1.26–2.24) (26). All results were in agreement with 
our findings for patients with SSc. Similarly, the HR for 
all-cause mortality in patients with SSc is in agreement 
with earlier finding (27).
A Swedish study examined whether there was an 
association between hospital admission in a variety of 
immune-mediated diseases, one of which was LS, and 
subsequent risk of hospitalization for coronary heart 
disease (CHD) (28). The study did not show any clear 
results for LS. Depending on the division of the data, the 
risk of having CHD was either increased or decreased. 
If the age at diagnosis of CHD was < 50 years then the 
Table II. Follow-up time (person-years), number of events and 








Person-years 62,986,301 6,122 13,370
Number of events 506,536 49 310
Incidence rates 8.04 8.00  23.10
All-cause mortality
Person-years 64,054,795 6,251 13,905
Number of events 753,838 77 549
Incidence rates 11.77 12.32 39.48
aStroke, acute myocardial infarction and cardiovascular death.
CVD: cardiovascular disease.
Table III. Hazard ratio (HR) and 95% confidence interval (CI) for 
composite cardiovascular disease (CVD) endpoint and all-cause 
mortality for patients diagnosed with localized scleroderma and 
systemic sclerosis and adjusted for age, calendar year, concomitant 
medication, comorbidity, socioeconomic status and sex








p-value 0.765 < 0.001
aStroke, acute myocardial infarction and cardiovascular death. bCalculated by 
comparing patients with local scleroderma and those with systemic sclerosis with 
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standardized incidence ratio (SIR) for subsequent CHD, 
after one year of follow-up, was 0.98 (95% CI 0–5.62), 
and if the age at diagnosis of CHD was ≥ 70 years then 
the SIR was 1.28 (95% CI 1.28–1.49) after one year 
of follow-up. Our study did not find an increased risk 
when the data were stratified into age categories. In the 
Swedish study, the overall SIR for CHD for patients 
with LS was 1.24 (95% CI 1.07–1.43); however, the 
majority of the results were not significant. In addition, 
the study was limited by low numbers of participants 
with LS, and it only included hospitalized patients with 
LS; hence, it might not represent the risk of developing 
CHD for all patients with LS, as most patients with 
LS are not hospitalized (28). Our study included both 
inpatients and outpatients and the LS group comprised 
almost 3.5-fold as many patients. The same authors 
performed a similar study, in which the endpoint was 
ischaemic and haemorrhagic stroke (29). The trend for 
LS was the same, with several insignificant results and 
a low numbers of participants.
Study limitations and strengths
The present study has some limitations. No data on tra-
ditional cardiovascular risk factors, such as body mass 
index, diet and smoking, were included. Information on 
smoking is not available in the databases; however, we in-
directly adjusted for smoking using socioeconomic status 
and via chronic obstructive pulmonary disease (30, 31).
Another limitation is that some patients with LS are 
followed by their private dermatologist or general prac-
titioner, and our results cannot be generalized to these 
patients. However, the most severely affected patients are 
followed at a hospital. Misclassification of patients with 
LS as references would tend to bias the results towards 
having no differences in risk of CVD. Moreover, this 
limitation should not be present in patients with SSc, as, 
in Denmark, they are traditionally followed at a hospital. 
A further limitation is that we did not evaluate the dif-
ferent subtypes of LS. 
The diagnoses of LS and SSc in the Danish National 
Patient Registry have not been validated previously. We 
found IRs of 1.1 per 100,000 person-years and 3.1 events 
per 100,000 person-years for LS and SSc, respectively. 
Previously reported IRs varied greatly according to the 
geographical location and study design (32–35). Our 
IRs are not directly comparable with the findings of 
previous studies due to different geographical location, 
calendar-year and study design, but the results are almost 
in agreement with earlier findings (32–35). 
We did not investigate change in CVD during the 
study period. 
The use of the Charlson comorbidity index as a sum-
mary score to adjust for comorbidities is widely accepted; 
however, it is important to acknowledge that the index 
has not been validated in selected populations without 
previous cardiovascular events and may not be an ac-
curate predictor of mortality in this setting.
The Danish population is predominantly of Cauca-
sian descent, and extrapolation of results to patients 
of other ethnicities should be carried out with caution. 
Ethnicity affects the incidence and prevalence, with 
Afro-Americans having higher incidence and prevalence 
than Caucasians (33). 
The large number of participants, the nationwide co-
verage of recorded registries, no loss to follow-up and 
the long duration of the follow-up period represent major 
strengths. The nationwide coverage minimized selection 
bias, compared with data obtained from highly speciali-
zed centres. Also, the use of nationwide, prospectively 
recorded registries eliminated recall bias. Finally, the 
results were supported by the sensitivity analyses ac-
counting for changes in comorbidities during follow-up 
and stratification of age.
Conclusion 
In this nationwide study, SSc, but not LS, was a signifi-
cant cardiovascular risk factor for the composite endpoint 
of stroke, myocardial infarction, and cardiovascular 
death, and for all-cause mortality.
Patients with SSc should be advised and evaluated 
regarding traditional cardiovascular risk factors, so that 
the overall risk for the individual patient can be deter-
mined. It is new and useful knowledge that patients with 
LS do not have increased risk for CVD and reassuring 
that these patients can follow the same guidelines as the 
general population.
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